Details of the Drug
General Information of Drug (ID: DMTGRAF)
Drug Name |
Imidazolidin-2-ylidene-o-tolyl-amine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
36318-56-6; Imidazolidine, 2-(2-methylphenylimino)-; N-(2-methylphenyl)-4,5-dihydro-1H-imidazol-2-amine; CHEMBL50430; 785724-64-3; (4,5-dihydro-1H-imidazol-2-yl)-o-tolyl-amine; Imidazolidine,2-(2-methylphenylimino)-; AC1L3KDH; Benzenamine,N-2-imidazolidinylidene-2-methyl-; SCHEMBL8020019; CTK5E5913; CTK1C4679; DTXSID30189852; WLQWOUULTDRZTQ-UHFFFAOYSA-N; ZINC13835980; BDBM50213213; 2-(2-Methylphenylimino)imidazolidine; 2-(2-methylphenylimino)-imidazolidine; AKOS027415754; KB-298713
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 175.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||